Merck Serono Initiates Phase III Trial Of Safinamide In Early Parkinson’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck KGaA has initiated a new Phase III study evaluating the alpha aminoamide derivative safinamide in patients with early Parkinson's disease with changes to dosing and the primary efficacy endpoint informed by the results of an earlier failed trial